Immix Biopharma Prices $150M Public Offering at Market Price Following Strong Clinical Data
IMMX has more than doubled off its 52-week low of $1.87 on elevated volume (7.0× avg).
Summary
Immix Biopharma announced the pricing of a $150 million public offering at market price, capitalizing on recent positive clinical trial results for its lead drug candidate and significantly extending its cash runway.
Key Events · Financing and Capital Events · IMMX
-
Prices $150 Million Public Offering
Immix Biopharma priced an underwritten public offering of 16,778,524 shares of common stock, generating approximately $141 million in net proceeds before expenses.
-
Offering Priced at Market
The shares were priced at $8.94, matching the closing price on May 20, 2026, indicating strong demand and favorable terms for the capital raise.
-
Significant Dilution
The offering will increase the number of outstanding shares by approximately 24%, resulting in substantial dilution for existing shareholders.
-
Extends Cash Runway
The net proceeds are intended to fund NXC-201 clinical development, working capital, and general corporate purposes, extending the company's operational needs into mid-2028.
Analysis · IMMX · Life Sciences
Immix Biopharma has priced a significant underwritten public offering of 16,778,524 shares of common stock, raising approximately $141 million in net proceeds. The offering was priced at $8.94 per share, matching the closing price on May 20, 2026, which is a favorable term for a capital raise of this magnitude. This substantial capital infusion, representing over 30% of the company's market capitalization, is strategically timed immediately after the announcement of highly positive Phase 2 clinical trial results for its lead candidate, NXC-201, showing a 95% complete response rate. While the offering is highly dilutive, increasing outstanding shares by approximately 24%, it significantly extends the company's cash runway into mid-2028, providing critical funding for NXC-201 clinical development and general corporate purposes. The ability to secure such a large amount of capital at market price, rather than a discount, underscores institutional confidence following the positive clinical data.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMMX was trading at $8.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $471.7M. The 52-week trading range was $1.87 to $11.61. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.